2. Search Result
Search Result
Results for "

current amplitudes

" in MedChemExpress (MCE) Product Catalog:

22

Inhibitors & Agonists

6

Peptides

2

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-110175
    CX614
    1 Publications Verification

    		 iGluR Neurological Disease
    CX614 is a positive variant modulator of AMPA receptors that enhances excitatory postsynaptic potentials (amplitude and duration) by blocking and slowing the inactivation of responses to glutamate and automatically evokes excitatory postsynaptic currents in neuronal cultures. CX614 can be used in the study of psychiatric disorders such as depression .
    CX614
  • HY-P11117
    TAT-EE3

    		TRP Channel iGluR Calcium Channel Neurological Disease
    TAT-EE3 is a neuroprotective peptide which can uncouple TRPM2-NMDARs interaction. TAT-EE3 inhibits TRPM2-induced enhancement of NMDAR surface expression and current amplitude.TAT-EE3 protects neurons against ischemic injury in vitro and in vivo. TAT-EE3can be used for the study of ischemic stroke .
    TAT-EE3
  • HY-108588
    NS5806
    1 Publications Verification

    		 Potassium Channel Cardiovascular Disease
    NS5806, a potent potassium current activator, increases KV4.3/KChIP2 peak current amplitudes with an EC50 of 5.3 μM. NS5806 slows KV4.3 and KV4.2 current dacay in channel complexes containing KChIP2 .
    NS5806
  • HY-N6688
    Verruculogen

    		Potassium Channel Bacterial Infection Neurological Disease
    Verruculogen is a tremorgenic mycotoxin and inhibitor of the M phase of the mammalian cell cycle. Verruculogen is produced by Penicillium and Aspergillus species. Verruculogen enhances the binding of ChTX to maxi-k channels with a K1/2 value of 170 nM. Verruculogen inhibits the amplitude of Ca 2+-activated K + currents. Verruculogen induces severe tremors in infected animals .
    Verruculogen
  • HY-124702
    ICA-105574
    1 Publications Verification

    		 Potassium Channel Cardiovascular Disease
    ICA-105574 is a potent and efficacious hERG channel activator. The primary mechanism by which ICA-105574 potentiates hERG channel activity is by removing hERG channel inactivation. ICA-105574 steeply potentiates current amplitudes more than 10-fold with an EC50 value of 0.5 +/- 0.1 μM and a Hill slope (n(H)) of 3.3 +/- 0.2. ICA-105574 can prevent arrhythmias induced by cardiac delayed repolarization. ICA-105574 shortens action potential duration in ventricular myocytes concentration-dependently .
    ICA-105574
  • HY-110162
    QO 58

    		Potassium Channel Neurological Disease
    QO 58 is a potent modulator of K(v)7 channels. QO-58 increases the current amplitudes, shifts the voltage-dependent activation curve in a more negative direction and slows the deactivation of K(v)7.2/K(v)7.3 currents. QO-58 has the potential for the research of diseases associated with neuronal hyperexcitability .
    QO 58
  • HY-108592
    UCL 2077

    		Potassium Channel Cardiovascular Disease Neurological Disease
    UCL 2077 is a potassium channel and slow afterhyperpolarization (sAHP) inhibitor. UCL 2077 selectively blocks sAHP channels without affecting L-type Ca 2+ currents. UCL 2077 blocks KCNQ1- and KCNQ2-containing K + channels, decreases erg current amplitude, increases erg deactivation rate. UCL 2077 can be used for the research of hippocampus-dependent memory retrieval deficit and cardiac arrhythmias .
    UCL 2077
  • HY-W014883
    1,12-Dodecanediamine

    1,12-DD; 1,12-Diamino dodecane

    		 Potassium Channel Metabolic Disease
    1,12-Dodecanediamine (1,12-DD) is a reversible Maxi calcium-activated potassium channel blocker. 1,12-Dodecanediamine can reduce the single-channel current amplitude, mean channel open time, and channel open probability. 1,12-Dodecanediamine is promising for research of cell electrical signal transduction mechanism .
    1,12-Dodecanediamine
  • HY-N8472
    Chrodrimanin B

    		GABA Receptor Infection
    Chrodrimanin B, a metabolite of a fungal, is a potent, non-open-channel-blocking antagonist on?B.?mori GABAR RDL with an IC50?of 1.13 nM. Chrodrimanin B attenuates the peak current amplitude of the GABA response of RDL with an IC50?of 1.66 nM.?Chrodrimanin B, a meroterpenoid, shows insecticidal activity .
    Chrodrimanin B
  • HY-176065
    Nav1.2-IN-1

    		Sodium Channel Neurological Disease
    Nav1.2-IN-1 (compound 5i), a 3-(1,2,3,6-tetrahydropyridine)-4-azaindole derivative, is a potent and selective Nav1.2 inhibitor. Nav1.2-IN-1 induces a reduction in the peak amplitude of Nav1.2 currents with an IC50 value of 7.79 μM. Nav1.2-IN-1 exhibits antiepileptic activity. Nav1.2-IN-1 shows high anticonvulsant effect and low neurotoxicity in subcutaneous Pentetrazole (sc-PTZ)-induced epilepsy mode .
    Nav1.2-IN-1
  • HY-113673
    A-935142

    		Potassium Channel Cardiovascular Disease
    A-935142 is a human ether-a-go-go-related gene (hERG, Kv 11.1) channel activator. A-935142 enhances hERG current in a complex manner by facilitation of activation, reduction of inactivation, and slowing of deactivation, and abbreviates atrial and ventricular repolarization .
    A-935142
  • HY-108502
    KC 12291 hydrochloride

    		Sodium Channel Cardiovascular Disease
    KC 12291 hydrochloride is an orally active blocker of voltage-gated sodium channel (VGSC). KC 12291 hydrochloride reduces the amplitude of sustained Na + current to exert antiischemic activity. KC 12291 hydrochloride has significant cardioprotective effect in vitro and in vivo .
    KC 12291 hydrochloride
  • HY-P3777
    β-Bag cell peptide

    		Potassium Channel Neurological Disease
    β-Bag cell peptide is a neuroactive peptide. β-Bag cell peptide elevates cyclic AMP levels in the bag cell neurons. β-Bag cell peptide decreases the amplitudes of the voltage-dependent potassium currents .
    β-Bag cell peptide
  • HY-P1249
    Neuropeptide SF(mouse,rat)

    		Neuropeptide Y Receptor Neurological Disease
    Neuropeptide SF (mouse,rat) is a potent neuropeptide FF receptor agonist with Ki values are 48.4 nM and 12.1 nM for NPFF1 and NPFF2, respectively. Neuropeptide SF increases the amplitude of the sustained current of heterologously expressed acid sensing ion channel 3 (ASIC3) .
    Neuropeptide SF(mouse,rat)
  • HY-P1249A
    Neuropeptide SF(mouse,rat) TFA

    		Neuropeptide Y Receptor Neurological Disease
    Neuropeptide SF (mouse,rat) TFA is a potent neuropeptide FF receptor agonist with Ki values are 48.4 nM and 12.1 nM for NPFF1 and NPFF2, respectively. Neuropeptide SF TFA increases the amplitude of the sustained current of heterologously expressed acid sensing ion channel 3 (ASIC3) .
    Neuropeptide SF(mouse,rat) TFA
  • HY-131885
    RuBi-Glutamate hexafluorophosphate sodium

    		GABA Receptor Neurological Disease
    RuBi-Glutamate hexafluorophosphate sodium is a neuronal activator. RuBi-Glutamate hexafluorophosphate sodium photocleaves to release glutamate upon one- or two-photon excitation, activating glutamate receptors in cortical pyramidal neurons. RuBi-Glutamate hexafluorophosphate sodium reduces peak amplitude of evoked GABAergic inhibitory postsynaptic currents in its caged form. RuBi-Glutamate hexafluorophosphate sodium can be used for the research of Huntington's disease .
    RuBi-Glutamate hexafluorophosphate sodium
  • HY-178928
    KV1.3-IN-3

    		Potassium Channel Inflammation/Immunology
    KV1.3-IN-3 (Compound 13a) is a KV1.3 channel inhibitor. KV1.3-IN-3 decreases the Kv1.3 peak current amplitude by more than 80%. KV1.3-IN-3 exhibits excellent pharmacological properties and safety. KV1.3-IN-3 can be used for the study of autoimmunity disease .
    KV1.3-IN-3
  • HY-108588R
    NS5806 (Standard)

    		Reference Standards Potassium Channel Cardiovascular Disease
    NS5806 (Standard) is the analytical standard of NS5806 (HY-108588). This product is intended for research and analytical applications. NS5806, a potent potassium current activator, increases KV4.3/KChIP2 peak current amplitudes with an EC50 of 5.3 μM. NS5806 slows KV4.3 and KV4.2 current dacay in channel complexes containing KChIP2 .
    NS5806 (Standard)
  • HY-P1059
    Pep2-AVKI

    		iGluR Neurological Disease
    Pep2-AVKI is a selective peptide inhibitor of the binding of the AMPA receptor subunit (GluR2) at the C-terminal PDZ site to C-kinase (PICK1). Pep2-AVKI does not affect the binding of (AMPA-type glutamate receptor) GluA2 to GRIP or ABP. Pep2-AVKI does not increase the amplitude of AMPA currents. pep2-AVKI can be used to study neurological diseases .
    Pep2-AVKI
  • HY-W714853
    (+)-Theta-cypermethrin

    		Akt Src STAT EGFR Drug Isomer Neurological Disease Inflammation/Immunology
    (+)-Theta-cypermethrin is a stereoisomer of Cypermethrin (HY-B0829) that possesses blood-brain barrier penetration ability and binds to AKT1, SRC, STAT3 and EGFR with high affinity. (+)-Theta-cypermethrin reduces the amplitude of delayed rectifier potassium channel currents, shifts the steady-state activation curve to negative potentials, and shifts the steady-state inactivation curve to negative potentials at higher concentrations. (+)-Theta-cypermethrin induces abnormal electrical activity in rat hippocampal neurons. (+)-Theta-cypermethrin causes chronic respiratory system damage and exhibits neurotoxicity .
    (+)-Theta-cypermethrin
  • HY-P1056
    pep2-SVKI

    		iGluR Neurological Disease
    pep2-SVKI is a selective peptide inhibitor. pep2-SVKI inhibits the binding of AMPA-type glutamate receptor (GluA2) (C-terminal PDZ site) to glutamate receptor interacting protein (GRIP), AMPA receptor binding protein (ABP), and C-kinase interacting protein (PICK1). pep2-SVKI increases the amplitude of AMPA receptor-mediated currents and blocks long-term depression (LTD). pep2-SVKI can be used to study neurological diseases .
    pep2-SVKI
  • HY-Y0282
    Sodium bromide

    NSC 77384; Sanibrom 40

    		 Environmental Pollutants Neurological Disease
    Sodium bromide (NSC 77384; Sanibrom 40) is a GABA-ergic system modulator that crosses the blood-brain barrier, and it effectively reduces and blocks epileptiform discharges. Sodium bromide exerts significant anticonvulsant effects by enhancing GABA-ergic inhibitory functions, such as increasing the amplitude of inhibitory postsynaptic currents and paired-pulse inhibition. Sodium bromide specifically enhances stimulation-induced extracellular alkalosis without affecting baseline pH or subsequent acidosis processes. Sodium bromide exhibits species-specific pharmacokinetic characteristics, competes with chloride ions for renal tubular reabsorption sites, and serves as a marker for extracellular fluid volume. Sodium bromide can be used in the research of epilepsy and related neurological diseases .
    Sodium bromide

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: